Cargando…

Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability

Antipsychotics are recommended for the treatment of impulsive dyscontrol and cognitive perceptual symptoms of borderline personality disorder (BPD). Three reports supported the efficacy of oral risperidone on BPD psychopathology. Paliperidone ER is the metabolite of risperidone with a similar mechan...

Descripción completa

Detalles Bibliográficos
Autores principales: Bellino, Silvio, Bozzatello, Paola, Rinaldi, Camilla, Bogetto, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3151513/
https://www.ncbi.nlm.nih.gov/pubmed/21826264
http://dx.doi.org/10.1155/2011/680194
_version_ 1782209625220710400
author Bellino, Silvio
Bozzatello, Paola
Rinaldi, Camilla
Bogetto, Filippo
author_facet Bellino, Silvio
Bozzatello, Paola
Rinaldi, Camilla
Bogetto, Filippo
author_sort Bellino, Silvio
collection PubMed
description Antipsychotics are recommended for the treatment of impulsive dyscontrol and cognitive perceptual symptoms of borderline personality disorder (BPD). Three reports supported the efficacy of oral risperidone on BPD psychopathology. Paliperidone ER is the metabolite of risperidone with a similar mechanism of action, and its osmotic release reduces plasmatic fluctuations and antidopaminergic effects. The aim of this study is to evaluate efficacy and safety of paliperidone ER in BPD patients. 18 outpatients with a DSM-IV-TR diagnosis of BPD were treated for 12 weeks with paliperidone ER (3–6 mg/day). They were assessed at baseline, week 4, and week 12, using the CGI-Severity item, the BPRS, the HDRS, the HARS, the SOFAS, the BPD Severity Index (BPDSI), and the Barratt Impulsiveness Scale (BIS-11). Adverse events were evaluated with the DOTES. Paliperidone ER was shown to be effective and well tolerated in reducing severity of global symptomatology and specific BPD symptoms, such as impulsive dyscontrol, anger, and cognitive-perceptual disturbances. Results need to be replicated in controlled trials.
format Online
Article
Text
id pubmed-3151513
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-31515132011-08-08 Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability Bellino, Silvio Bozzatello, Paola Rinaldi, Camilla Bogetto, Filippo Depress Res Treat Research Article Antipsychotics are recommended for the treatment of impulsive dyscontrol and cognitive perceptual symptoms of borderline personality disorder (BPD). Three reports supported the efficacy of oral risperidone on BPD psychopathology. Paliperidone ER is the metabolite of risperidone with a similar mechanism of action, and its osmotic release reduces plasmatic fluctuations and antidopaminergic effects. The aim of this study is to evaluate efficacy and safety of paliperidone ER in BPD patients. 18 outpatients with a DSM-IV-TR diagnosis of BPD were treated for 12 weeks with paliperidone ER (3–6 mg/day). They were assessed at baseline, week 4, and week 12, using the CGI-Severity item, the BPRS, the HDRS, the HARS, the SOFAS, the BPD Severity Index (BPDSI), and the Barratt Impulsiveness Scale (BIS-11). Adverse events were evaluated with the DOTES. Paliperidone ER was shown to be effective and well tolerated in reducing severity of global symptomatology and specific BPD symptoms, such as impulsive dyscontrol, anger, and cognitive-perceptual disturbances. Results need to be replicated in controlled trials. Hindawi Publishing Corporation 2011 2011-08-04 /pmc/articles/PMC3151513/ /pubmed/21826264 http://dx.doi.org/10.1155/2011/680194 Text en Copyright © 2011 Silvio Bellino et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Bellino, Silvio
Bozzatello, Paola
Rinaldi, Camilla
Bogetto, Filippo
Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability
title Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability
title_full Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability
title_fullStr Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability
title_full_unstemmed Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability
title_short Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability
title_sort paliperidone er in the treatment of borderline personality disorder: a pilot study of efficacy and tolerability
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3151513/
https://www.ncbi.nlm.nih.gov/pubmed/21826264
http://dx.doi.org/10.1155/2011/680194
work_keys_str_mv AT bellinosilvio paliperidoneerinthetreatmentofborderlinepersonalitydisorderapilotstudyofefficacyandtolerability
AT bozzatellopaola paliperidoneerinthetreatmentofborderlinepersonalitydisorderapilotstudyofefficacyandtolerability
AT rinaldicamilla paliperidoneerinthetreatmentofborderlinepersonalitydisorderapilotstudyofefficacyandtolerability
AT bogettofilippo paliperidoneerinthetreatmentofborderlinepersonalitydisorderapilotstudyofefficacyandtolerability